I need Don Pescado to scream “The science is cooooomingggg!!” Insilico does it gain…it’s the 10th AI generated drug they created that reaches clinical stage! This is simply amazing!
ISM5939 is a novel, potent, orally available, and selective inhibitor of the enzyme ENPP1. It is being investigated as an anti-tumor agent due to its ability to enhance the anti-tumor effects of immune checkpoint inhibitors. ISM5939 has shown efficacy in syngeneic murine models of colorectal carcinoma (MC-38 and CT-26), and its potent inhibition of ENPP1 is thought to prevent the breakdown of cGAMP, a key molecule in the activation of the cGAS-STING pathway. This pathway plays a critical role in boosting anti-tumor immune responses (in prostate cancer as well if I remember correctly).
While the original source does not mention if ISM5939 would be effective against prostate cancer specifically, ENPP1 has been linked to prostate cancer. One study ( pmc.ncbi.nlm.nih.gov/articl... )identified ENPP1 as part of a 14-gene cluster associated with bone metastasis in metastatic castration-resistant prostate cancer (mCRPC). But further investigations are due…
Monoamine oxidase A (MAOA): A promising target for prostate cancer therapy
Risk Management (Taleb-style) meets Adaptive Theory (Moffitt-style)